

Global Malignant Glioma Therapeutics Market Size study, by Type Of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma), by Therapy, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GA60657FDD2EEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: GA60657FDD2EEN

Abstracts

Global Malignant Glioma Therapeutics Market is valued approximately at USD 1.54 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 10.26% over the forecast period 2024-2032. Malignant gliomas, representing some of the most aggressive and lethal forms of brain tumors, have long posed formidable challenges to the medical community. Among them, glioblastoma multiforme stands as the most common and deadliest variant, notoriously resistant to conventional therapeutic modalities. As the global demand intensifies for more efficacious, patient-tailored treatment approaches, the malignant glioma therapeutics landscape is experiencing a paradigm shift—driven by innovation, collaboration, and urgency. The market is being actively reshaped by cutting-edge developments in immunotherapy, gene-based treatments, and advanced drug delivery systems designed to overcome the formidable blood-brain barrier, offering a glimmer of hope in a historically under-treated field.

The increasing incidence of malignant brain tumors globally, coupled with the rising aging population, is intensifying the urgency for targeted therapeutics. Patients are increasingly being diagnosed earlier thanks to enhanced neuroimaging techniques and rising awareness surrounding neurological symptoms, thus expanding the therapeutic window. Moreover, major biotech and pharmaceutical players are investing heavily in R&D to develop novel compounds and combination therapies. These include tumor-treating fields (TTF), personalized vaccines, and CAR T-cell therapies specifically engineered for glioma subtypes. However, despite these promising developments, the market continues to face bottlenecks such as high treatment costs, regulatory complexity, and limited penetration in lower-income economies.

In the wake of these challenges, numerous initiatives have emerged to bridge the therapeutic gap. Multinational consortia are focusing on clinical trials that integrate molecular profiling and artificial intelligence to optimize therapeutic decision-making. Precision medicine is quickly becoming the new standard, with biomarker-driven treatment pathways gaining prominence in the oncology community. Additionally, partnerships between biotech startups and large pharmaceutical firms are accelerating time-to-market for next-generation therapeutics. The oncology segment of the biopharma industry has seen increased regulatory support for orphan drugs and accelerated approvals for glioma-related therapeutics, particularly in the U.S. and Europe. These policy tailwinds are not only de-risking innovation but also encouraging early-stage development in niche indications like glioma.

Technological breakthroughs in nanomedicine and blood-brain barrier disruption are opening previously inaccessible doors for effective glioma drug delivery. New-age delivery mechanisms such as liposomal formulations and convection-enhanced delivery are enabling higher drug concentrations at tumor sites with reduced systemic toxicity. Concurrently, real-time imaging and intraoperative mapping technologies are augmenting surgical resection outcomes—allowing for more comprehensive treatment regimens that include adjuvant chemotherapies and radiation. The integration of big data analytics and AI into clinical research is further enhancing trial design, patient recruitment, and adaptive treatment protocols—driving both clinical efficacy and commercial viability.

Geographically, North America commands a dominant share in the malignant glioma therapeutics market, owing to a sophisticated healthcare infrastructure, a high concentration of specialized neuro-oncology centers, and proactive regulatory frameworks that support accelerated approvals. Europe closely follows, propelled by strong academic-industry collaborations, rising incidence rates, and substantial public healthcare investment in rare disease treatment. Meanwhile, the Asia Pacific region is projected to experience the fastest growth over the forecast horizon, driven by improving diagnostic capabilities, increasing patient awareness, and growing government support for oncology drug development in emerging economies like China and India. Latin America and the Middle East & Africa are also witnessing gradual expansion, bolstered by rising healthcare expenditure and international initiatives aimed at strengthening neuro-oncology care in underserved regions.

Major market player included in this report are:

Novartis AG

F. Hoffmann-La Roche AG

Merck & Co., Inc.

Pfizer Inc.

Amgen Inc.

Bristol-Myers Squibb Company

AstraZeneca PLC

Eli Lilly and Company

Bayer AG

Sanofi S.A.

Teva Pharmaceutical Industries Ltd.

AbbVie Inc.

Takeda Pharmaceutical Company Limited

GlaxoSmithKline plc

Sumitomo Pharma Co., Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type Of Disease

Glioblastoma Multiforme

Anaplastic Astrocytoma

By Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

Radiation Therapy

Surgery

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET EXECUTIVE SUMMARY

- 1.1. Global Malignant Glioma Therapeutics Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Type of Disease
 - 1.3.2. By Therapy
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Incidence of Malignant Brain Tumors and Aging Population
- 3.1.2. Enhanced Neuroimaging Techniques and Early Diagnosis
- 3.1.3. Surge in Biotech & Pharma R&D Investments

3.2. Market Challenges

- 3.2.1. High Treatment Costs
- 3.2.2. Regulatory Complexity and Approval Bottlenecks
- 3.2.3. Limited Penetration in Lower-Income Economies

3.3. Market Opportunities

- 3.3.1. Precision Medicine and Biomarker-Driven Therapies
- 3.3.2. Advances in Nanomedicine & Blood-Brain Barrier Disruption
- 3.3.3. Regulatory Support for Orphan Drugs and Accelerated Approvals

CHAPTER 4. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's 5 Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspectives

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET SIZE &

FORECASTS BY TYPE OF DISEASE (2022–2032)

- 5.1. Segment Dashboard
- 5.2. Glioblastoma Multiforme: Revenue Trend Analysis, 2022 & 2032
- 5.3. Anaplastic Astrocytoma: Revenue Trend Analysis, 2022 & 2032

CHAPTER 6. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET SIZE & FORECASTS BY THERAPY (2022–2032)

- 6.1. Segment Dashboard
- 6.2. Chemotherapy: Revenue Trend Analysis, 2022 & 2032
- 6.3. Immunotherapy: Revenue Trend Analysis, 2022 & 2032
- 6.4. Targeted Therapy: Revenue Trend Analysis, 2022 & 2032
- 6.5. Radiation Therapy: Revenue Trend Analysis, 2022 & 2032
- 6.6. Surgery: Revenue Trend Analysis, 2022 & 2032
- 6.7. Others: Revenue Trend Analysis, 2022 & 2032

CHAPTER 7. GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET SIZE & FORECASTS BY REGION (2022–2032)

- 7.1. North America Market
 - 7.1.1. U.S. Market
 - 7.1.2. Canada Market
- 7.2. Europe Market
 - 7.2.1. UK Market
 - 7.2.2. Germany Market
 - 7.2.3. France Market
 - 7.2.4. Spain Market
 - 7.2.5. Italy Market
 - 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
 - 7.3.1. China Market
 - 7.3.2. India Market
 - 7.3.3. Japan Market
 - 7.3.4. Australia Market
 - 7.3.5. South Korea Market
 - 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
 - 7.4.1. Brazil Market

- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Novartis AG
 - 8.1.2. F. Hoffmann-La Roche AG
 - 8.1.3. Merck & Co., Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Novartis AG
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Pfizer Inc.
 - 8.3.3. Amgen Inc.
 - 8.3.4. Bristol-Myers Squibb Company
 - 8.3.5. AstraZeneca PLC
 - 8.3.6. Eli Lilly and Company
 - 8.3.7. Bayer AG
 - 8.3.8. Sanofi S.A.
 - 8.3.9. Teva Pharmaceutical Industries Ltd.
 - 8.3.10. AbbVie Inc.
 - 8.3.11. Takeda Pharmaceutical Company Limited
 - 8.3.12. GlaxoSmithKline plc
 - 8.3.13. Sumitomo Pharma Co., Ltd.

CHAPTER 9. RESEARCH PROCESS

- 9.1. Research Process
 - 9.1.1. Data Mining
 - 9.1.2. Analysis

- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes

I would like to order

Product name: Global Malignant Glioma Therapeutics Market Size study, by Type Of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma), by Therapy, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GA60657FDD2EEN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA60657FDD2EEN.html>